Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) have become standard treatment in different tumor entities. However, safe treatment with ICI targeting the PD-1/PD-L1 axis requires early detection of immune-related adverse events (irAE). There exist different questionnaires of drug manufacturers for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Griewing, Luisa Maria, Schweizer, Claudia, Schubert, Philipp, Rutzner, Sandra, Eckstein, Markus, Frey, Benjamin, Haderlein, Marlen, Weissmann, Thomas, Semrau, Sabine, Gostian, Antoniu-Oreste, Müller, Sarina K., Traxdorf, Maximilian, Iro, Heinrich, Zhou, Jian-Guo, Gaipl, Udo S., Fietkau, Rainer, Hecht, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992796/
https://www.ncbi.nlm.nih.gov/pubmed/33761922
http://dx.doi.org/10.1186/s12885-021-08006-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992796/
https://www.ncbi.nlm.nih.gov/pubmed/33761922
http://dx.doi.org/10.1186/s12885-021-08006-0

Ejemplares similares